Review began 11/10/2021
Review ended 12/02/2021
Published 12/07/2021

© Copyright 2021

Houpt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Assessing Psychiatric Comorbidity and Pharmacologic Treatment Patterns Among Patients With Neurofibromatosis Type 1

Alexander C. Houpt¹, Shaina E. Schwartz¹, Robert A. Coover²

1. Clinical Sciences, High Point University Fred Wilson School of Pharmacy, High Point, USA 2. Basic Pharmaceutical Sciences, High Point University Fred Wilson School of Pharmacy, High Point, USA

Corresponding author: Shaina E. Schwartz, shainaeschwartz@gmail.com

Abstract

Background and objective

Neurofibromatosis 1 (NF1) is a genetic disorder that is accompanied by psychiatric comorbidities such as depression, anxiety, and attention-deficit hyperactivity disorder (ADHD) in more than half of the patients. However, there are limited data describing optimal treatment strategies for these conditions. This study aimed to address that gap in understanding and explore the neurobiological basis of psychiatric comorbidities in NF1.

Materials and methods

A retrospective cohort study was conducted among NF1 patients with a comorbid diagnosis of depression, anxiety, and/or ADHD. These disease states were chosen based on their relatively high reported prevalence in NF1 and shared pathophysiological mechanisms via monoaminergic dysfunction. Information regarding demographics, psychotherapeutic medication use, and clinical outcomes was gathered from electronic medical records. Relationships between patient- and medication-related factors and outcome measures were assessed using statistical analysis.

Results

The study population (n = 82) consisted of NF1 patients with a comorbid diagnosis of depression (76.8%), anxiety (53.7%), and/or ADHD (23.2%). The use of second-generation antipsychotic agent augmentation therapy or hydroxyzine monotherapy was associated with significantly more behavioral health (BH)-related emergency department (ED) visits, admissions, and inpatient days in the study population. Conversely, the use of bupropion augmentation therapy, buspirone augmentation therapy, and stimulants was associated with improved clinical outcomes, though these results were not statistically significant.

Conclusions

Based on our findings in this real-world study setting, patients with NF1 and psychiatric comorbidities appear to experience significant benefits from medications that enhance dopaminergic neurotransmission (e.g., bupropion, stimulants) when compared to drugs that oppose it (e.g., second-generation antipsychotics).

Categories: Neurology, Pediatrics, Psychiatry

Keywords: antipsychotic, antidepressant, treatment, psychopharmacology, attention-deficit/hyperactivity disorder, anxiety, depression, neurofibromatosis type 1

Introduction

Neurofibromatosis type 1 (NF1) is an autosomal-dominant disorder arising from a mutation in the gene encoding neurofibromin, a tumor suppressor protein involved in activating the RasGAP pathway, which regulates cell growth and differentiation [1,2]. Hallmark symptoms of NF1 involve darkening of the skin and the development of benign neurofibromas that vary in size, shape, and location [1,2]. NF1 is one of the most common neurogenetic disorders, with an estimated incidence rate of one in 3,000 people at birth [3]. Its manifestation begins in childhood and results in a significantly shortened lifespan (median age at death: 59 years, compared to 74 years for the general population in the United States) [4].

Quality of life and psychosocial functioning are notably impaired in patients with NF1 [5,6]. Consequently, this patient population has a higher rate of behavioral and emotional dysfunction [7-9], as well as certain psychiatric disorders [10,11]. The prevalence of autism spectrum disorder is speculated to be as high as 40% in this population [12-14], though a causative link has not yet been established [15]. Attention deficit hyperactivity disorder (ADHD) has also been observed in 38-49% of patients with NF1 [12,16-18] and can cause significant functional impairment [19]. Depression has been reported in an estimated 55% of patients

How to cite this article

Houpt A C, Schwartz S E, Coover R A (December 07, 2021) Assessing Psychiatric Comorbidity and Pharmacologic Treatment Patterns Among Patients With Neurofibromatosis Type 1. Cureus 13(12): e20244. DOI 10.7759/cureus.20244

and is particularly problematic due to its association with greater pain intensity in NF1 [6,20,21]. The prevalence of anxiety disorders in NF1 is not well studied but may be present in up to 15% of patients [6,22]. This is in addition to a wide array of cognitive deficits that may accompany the disease. Overall, approximately 80% of children with NF1 will present with a cognitive or behavioral issue [23].

The presence of psychiatric comorbidities in patients with NF1 is likely due in part to the high burden of disease [24], particularly related to skin lesions [25], but may also have a neurobiological basis that is not currently understood [26]. For example, learning deficits in patients with NF1 appear to arise from a different mechanism than ADHD in patients without NF1 [27,28]. The activity of specific neurotransmitter pathways may be implicated. Whole-brain serotonin levels were observed to be elevated in mice models of NF1 [29], and neurofibromin, which is dysregulated in NF1, assists in the activation of serotonin receptor subtype six (5-HT₆) [30]. With a decrease in the levels of neurofibromin, there is a concomitant lack of stimulation at the receptor resulting in decreased cyclic adenosine monophosphate (cAMP) and cAMP-responsive element-binding protein (CREB) levels, which are important in the regulation of cell survival, proliferation, and differentiation [30,31]. Antidepressants modulate the signaling pathways of monoamine neurotransmitters such as serotonin and have been studied with regard to the treatment of psychiatric symptoms in NF1. The use of imipramine and fluoxetine has been shown to increase neurogenesis and improve behavioral symptoms in NF1 mice [32]. These compounds directly stimulate the serotonin 5-HT receptor and may correct dysregulated signaling. Interestingly, the serotonin transporter gene SLC6A4 is susceptible to deletion in NF1 [33] but does not appear to be associated with depression in this population [34].

Evidence also suggests that animal models with NF1 have decreased levels of dopamine, though post-synaptic dopamine receptor expression remains unchanged [31,35,36]. Dopamine is important in the long-term potentiation of neurons, a process by which synapses are strengthened to aid in learning and memory formation [37]. The administration of either methylphenidate or L-dopa has been demonstrated to normalize dopamine levels, leading to an increase in attention-related and exploratory behavior in mice with NF1 [35,38]. This association is even stronger in a *Drosophila* NF1 knockdown, which displays hyperactivity that is ameliorated with methylphenidate [39]. ADHD has been previously linked to genes involved in dopaminergic neurotransmission as well as NF1 [40]. One hypothesis for the biological basis of cognitive dysfunction in NF1 implicates altered dopamine receptor binding [41]. Indeed, NF1 loss in dopamine receptor-expressing spiny neurons has been linked to motor learning delays [42]. The effect of NF1 mutation on learning and memory was linked to neuronal dopamine levels in a dose-dependent manner in animal models [43]. In vivo measurement of dopaminergic neurotransmission in NF1 mice confirms the reduced spontaneous firing [44].

While animal models offer insight into the potential pathogenesis and treatment of psychiatric conditions in patients with NF1, human data is currently scarce, which creates a critical gap in knowledge. This report seeks to provide insight into real-world patterns of medication use in NF1 patients who are diagnosed with psychiatric comorbidities. The primary outcome tested was the impact of medication-related factors on clinical indicators of disease severity [i.e., number of emergency department (ED) visits, admissions, and inpatient days for behavioral health (BH) reasons]. The secondary outcome tested was the impact of patient-related factors (i.e., age, sex, psychiatric diagnosis) on these indicators.

Materials And Methods

This retrospective descriptive analysis was conducted at an 80-bed non-profit BH hospital located in the southeastern United States. Patients were eligible for inclusion if they had an encounter through 1/1/2020 during which a diagnosis of NF1 [International Classification of Diseases (ICD) codes Q85.01 or 237.71] was applied. Patients were excluded from the study if they did not have a comorbid diagnosis of depression (F33), anxiety (F41), or ADHD (F90) on the problem list from the indexed encounter. This study was granted “exempt” status (rule #4) by the Institutional Review Boards at the participating hospital and university in October 2019.

Medical records were reviewed to determine the number of BH ED visits and admissions through 7/1/2020 for each eligible patient. Other information gathered included length of stay and any available treatment-related information (i.e., medication name, dose, duration, and augmentation). Medications were classified as monotherapy (if used alone) or augmentation (if used in combination with another medication indicated to treat the same condition).

Spearman’s rho test was used to calculate non-parametric correlations between continuous patient- and medication-related factors and clinical outcomes (i.e. BH ED visits, BH admissions, BH inpatient days), while Mann-Whitney U test was used to assess this relationship for categorical variables. All statistical analysis was performed using IBM® SPSS Statistics version 26 (IBM, Armonk, NY).

Results

The study population of patients with NF1 and a comorbid psychiatric diagnosis (n = 82) had a mean age of 44.5 years [range: 6-87 years, standard deviation (SD): 21.5 years] and were mostly female (69.5%) (Table 1).

The majority of the patients had a comorbid psychiatric diagnosis of depression (76.8%) or anxiety (53.7%), with 31 (37.8%) having multiple diagnoses. A smaller portion of patients (23.2%) were diagnosed with ADHD. At least one ED visit was noted on 16 patient charts (19.5%) and at least one BH admission was noted on 17 charts (20.7%). Twelve patients (14.6%) had at least one ED visit and BH admission during the study period.

Characteristic	Values (n = 82)
Mean age, years	44.5
Sex, n (%)	
Male	25 (30.5%)
Female	57 (69.5%)
Diagnosis of depression, n (%)	63 (76.8%)
Diagnosis of anxiety, n (%)	44 (53.7%)
Diagnosis of ADHD, n (%)	19 (23.2%)
History of BH ED visit, n (%)	16 (19.5%)
Total BH ED visits	30
History of BH admission, n (%)	17 (20.7%)
Total BH admissions	45
Total BH inpatient days	207
Antidepressant use, n (%)	54 (65.9%)
Total SSRI monotherapy	57
Total SNRI monotherapy	17
Total TCA monotherapy	1
Total bupropion monotherapy	7
Total SGA augmentation	10
Total bupropion augmentation	4
Anxiolytic use, n (%)	29 (35.4%)
Total benzodiazepine monotherapy	24
Total hydroxyzine monotherapy	8
Total buspirone monotherapy	5
Total hydroxyzine augmentation	4
Stimulant use, n (%)	10 (12.2%)
Non-stimulant use, n (%)	2 (2.4%)
SGA monotherapy use, n (%)	3 (3.7%)

TABLE 1: Baseline characteristics of the study population

ADHD: attention-deficit hyperactivity disorder; BH: behavioral health; ED: emergency department; SGA: second-generation antipsychotic; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant

Antidepressant therapy [i.e., selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs)] was utilized in 54 (65.9%) patients (65.9%), with many having a history of being prescribed multiple agents (Table 1). Anxiolytics therapy (i.e., benzodiazepines, buspirone, hydroxyzine) was utilized in 29 patients (35.4%). SSRIs were the most common agents prescribed (57 times) followed by benzodiazepines (24 times). Stimulant therapy was used to treat 10

patients (12.2%), while 17 patients (20.7%) in the study population were not being treated with any psychotherapeutic medications.

Age had a significant negative correlation with all clinical outcomes assessed, while the number of SSRIs and the total number of antidepressants positively correlated with BH admissions and inpatient days (Table 2). Similarly, a diagnosis of depression and the use of antidepressants were associated with a significantly higher number of BH admissions and inpatient days (Table 3). The use of second-generation antipsychotic (SGA) augmentation therapy and hydroxyzine monotherapy also emerged as significant positive predictors for all clinical outcomes investigated (Table 3).

Variables	BH ED visits	BH admissions	BH inpatient days
Age	$r_s = -0.284^* (p = 0.010)$	$r_s = -0.221^* (p = 0.046)$	$r_s = -0.253^* (p = 0.022)$
Number of SSRIs	$r_s = 0.217 (p = 0.050)$	$r_s = 0.354^* (p = 0.001)$	$r_s = 0.371^* (p = 0.001)$
Number of SNRIs	$r_s = 0.160 (p = 0.152)$	$r_s = 0.159 (p = 0.153)$	$r_s = 0.132 (p = 0.236)$
Number of TCAs	$r_s = -0.054 (p = 0.627)$	$r_s = -0.056 (p = 0.615)$	$r_s = -0.050 (p = 0.655)$
Number of total antidepressants	$r_s = 0.195 (p = 0.079)$	$r_s = 0.267^* (p = 0.015)$	$r_s = 0.272^* (p = 0.013)$
Number of benzodiazepines	$r_s = -0.033 (p = 0.771)$	$r_s = -0.039 (p = 0.725)$	$r_s = -0.051 (p = 0.652)$
Number of stimulants	$r_s = 0.104 (p = 0.351)$	$r_s = -0.079 (p = 0.480)$	$r_s = -0.047 (p = 0.677)$
Number of non-stimulants	$r_s = 0.150 (p = 0.178)$	$r_s = 0.132 (p = 0.236)$	$r_s = 0.163 (p = 0.143)$

TABLE 2: Patient characteristics as predictors for clinical outcomes based on Spearman’s rho test

*Denotes statistical significance (p: <0.05)

Continuous variables are reported as correlation coefficient (Spearman’s rho)

BH: behavioral health; ED: emergency department; SGA: second-generation antipsychotic; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant

Variables	BH ED visits	BH admissions	BH inpatient days
Sex	Male = 43.14, Female = 40.78, U = 672 (p = 0.550)	Male = 44.24, Female = 40.30, U = 644 (p = 0.330)	Male = 45.48, Female = 39.75, U = 613 (p = 0.126)
Depression	Yes = 42.69, No = 37.55, U = 674 (p = 0.232)	Yes = 44.06, No = 33.00, U = 760* (p = 0.012)	Yes = 43.61, No = 34.50, U = 732* (p = 0.026)
Anxiety	Yes = 40.13, No = 43.09, U = 776 (p = 0.415)	Yes = 39.60, No = 43.70, U = 753 (p = 0.273)	Yes = 40.18, No = 43.03, U = 778 (p = 0.411)
ADHD	Yes = 44.92, No = 40.47, U = 664 (p = 0.301)	Yes = 41.63, No = 41.46, U = 601 (p = 0.969)	Yes = 41.39, No = 41.53, U = 587 (p = 0.973)
Use of antidepressants	Yes = 43.36, No = 37.91, U = 857 (p = 0.154)	Yes = 44.41, No = 35.89, U = 913* (p = 0.030)	Yes = 44.29, No = 36.13, U = 907* (p = 0.035)
Bupropion monotherapy	Yes = 45.79, No = 41.10, U = 293 (p = 0.471)	Yes = 39.79, No = 41.66, U = 251 (p = 0.778)	Yes = 41.29, No = 41.52, U = 261 (p = 0.970)
Bupropion augmentation	Yes = 33.50, No = 41.91, U = 124 (p = 0.512)	Yes = 33.00, No = 41.94, U = 122 (p = 0.486)	Yes = 34.50, No = 41.86, U = 128 (p = 0.568)
SGA monotherapy	Yes = 61.83, No = 40.73, U = 180 (p = 0.139)	Yes = 62.67, No = 40.70, U = 182 (p = 0.125)	Yes = 65.17, No = 40.60, U = 190 (p = 0.081)
SGA augmentation	Yes = 55.30, No = 39.58, U = 498* (p = 0.005)	Yes = 60.15, No = 38.91, U = 547* (p = <0.001)	Yes = 60.30, No = 38.89, U = 548* (p = <0.001)
Use of benzodiazepines	Yes = 40.80, No = 41.76, U = 645 (p = 0.814)	Yes = 40.59, No = 41.83, U = 640 (p = 0.767)	Yes = 40.34, No = 41.93, U = 635 (p = 0.684)
Hydroxyzine monotherapy	Yes = 69.44, No = 38.48, U = 520* (p = <0.001)	Yes = 64.38, No = 39.03, U = 479* (p = <0.001)	Yes = 65.81, No = 38.87, U = 491* (p = <0.001)
Hydroxyzine augmentation	Yes = 44.75, No = 41.33, U = 169 (p = 0.795)	Yes = 54.50, No = 40.83, U = 208 (p = 0.279)	Yes = 56.38, No = 40.74, U = 216 (p = 0.209)
Buspirone monotherapy	Yes = 50.20, No = 40.94, U = 236 (p = 0.416)	Yes = 50.80, No = 40.90, U = 239 (p = 0.384)	Yes = 51.40, No = 40.86, U = 242 (p = 0.353)
Buspirone augmentation	Yes = 33.50, No = 41.60, U = 33 (p = 0.805)	Yes = 33.00, No = 41.60, U = 32 (p = 0.805)	Yes = 34.50, No = 41.59, U = 34 (p = 0.829)
Use of stimulants	Yes = 45.85, No = 40.90, U = 404 (p = 0.372)	Yes = 37.45, No = 42.06, U = 320 (p = 0.417)	Yes = 39.05, No = 41.84, U = 336 (p = 0.596)
Use of non-stimulants	Yes = 56.75, No = 41.12, U = 111 (p = 0.391)	Yes = 55.25, No = 41.16, U = 108 (p = 0.439)	Yes = 57.25, No = 41.11, U = 112 (p = 0.376)

TABLE 3: Patient characteristics as predictors for clinical outcomes based on Mann-Whitney U test

*Denotes statistical significance (p: <0.05)

Categorical variables are reported as mean rank with test statistics (Mann-Whitney U)

ADHD: attention-deficit hyperactivity disorder; BH: behavioral health; ED: emergency department; SGA: second-generation antipsychotic; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant

Discussion

Our examination of treatment patterns in patients with NF1 and a comorbid psychiatric diagnosis has revealed potential links between the neurobiological basis of these conditions and various pharmacological treatment approaches. Specifically, the modulation of dopamine signaling may be implicated based on the findings of the present study. The use of augmentation therapy with SGAs, which block dopamine receptors, was observed to have a negative impact on clinical outcomes in the study population. Conversely, it appears that the use of bupropion augmentation and stimulant medications, which enhance dopamine signaling via

reuptake inhibition mechanisms, may be associated with improved clinical outcomes, though these findings were not statistically significant. Buspirone augmentation therapy was also associated with a non-significant reduction in the primary outcome measures, but its effect on dopamine neurotransmission is complicated. Patients who were younger tended to have more ED visits and longer inpatient days, which makes it unlikely that the effects seen were results of psychiatric disease duration and/or treatment experience.

A year-long clinical study of children with NF1 found that the administration of the stimulant medication methylphenidate significantly improved cognitive and academic performance as well as social deficits [17]. Double-blind placebo-controlled crossover trials have demonstrated the efficacy of methylphenidate in reducing ADHD symptoms at four weeks [45] and cognitive symptoms at six weeks [46]. The efficacy of stimulants in patients with NF1 and ADHD has been theorized to relate to the predominance of the combined subtype in this population [47]. Though the present study did not find any significant links between the use of non-stimulant medications and clinical outcomes in patients with NF1, previous research suggests that guanfacine may ameliorate symptoms of ADHD in NF1 mouse models [48]. While the extent to which altered dopamine signaling in patients with NF1 impacts the treatment of psychiatric comorbidities remains unclear, the role of dopamine in the pathophysiology of depression has been previously explored. The dopamine agonist amantadine was studied among a small group of patients with treatment-resistant depression [49], and improvements were observed in both anxiety and depression scores [49], suggesting that dopamine plays a role in depression and anxiety, making it a potential treatment target.

There are several important limitations regarding the outcomes of this observational study. SGAs as augmentation therapy are generally reserved for patients who still experience depression or anxiety symptoms despite monotherapy treatment with a first-line agent. Patients in this study who were treated with SGAs had a higher rate of BH admissions, which may have been due to the severity of the patient's psychiatric condition rather than the antipsychotic medication itself. The association of a depression diagnosis, use of antidepressants, number of SSRIs, and total antidepressants with poorer clinical outcomes in the study population support the presence of a more acute subpopulation. It is not clear why hydroxyzine, an antihistamine agent often prescribed for its anxiolytic properties, was also linked to worse outcomes when used as monotherapy in this study, though its use in this manner is generally not recommended. A small sample size due to the rare nature of NF1 is another important limitation of this study.

While there was an association between the prescription of pro-dopaminergic agents and fewer BH ED visits, admissions, and inpatient days in the study population, there is insufficient evidence to definitively state that better outcomes were a direct result of the use of these medications. Future research into the relationship between dopamine and NF1 is needed to better define the role of dopamine-modulating agents in the treatment of psychiatric comorbidities in these patients.

Conclusions

Psychiatric comorbidities (depression, anxiety, and/or ADHD) are frequently observed in patients with NF1. Using BH ED visits, admissions, and inpatient days as clinical indicators, dopamine-blocking therapy with antipsychotic medications was found to be associated with worse outcomes, while dopamine-enhancing therapy with bupropion or stimulant medications was associated with improved outcomes. These findings suggest further areas of research to optimize the treatment of psychiatric comorbidities in patients with NF1.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Moses H. Cone Health System IRB issued approval 1512136. This study has been approved by the IRB at Moses H. Cone Health System. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors would like to acknowledge Dr. Sun Lee, PharmD for her assistance with statistical analysis.

References

1. Boyd KP, Korf BR, Theos A: Neurofibromatosis type 1. *J Am Acad Dermatol*. 2009, 61:1-14.

- 10.1016/j.jaad.2008.12.051
2. Jouhilahti EM, Peltonen S, Heape AM, Peltonen J: The pathoetiology of neurofibromatosis 1. *Am J Pathol.* 2011, 178:1932-9. [10.1016/j.ajpath.2010.12.056](#)
3. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ: Neurofibromatosis type 1. *Nat Rev Dis Primers.* 2017, 5:17004. [10.1038/nrdp.2017.4](#)
4. Rasmussen SA, Yang Q, Friedman JM: Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. *Am J Hum Genet.* 2001, 68:1110-8. [10.1086/320121](#)
5. Cipolletta S, Spina G, Spoto A: Psychosocial functioning, self-image, and quality of life in children and adolescents with neurofibromatosis type 1. *Child Care Health Dev.* 2018, 44:260-8. [10.1111/cch.12496](#)
6. Belzeaux R, Lançon C: Neurofibromatosis type 1: psychiatric disorders and quality of life impairment (Article in French). *Presse Med.* 2006, 35:277-80. [10.1016/s0755-4982\(06\)74570-5](#)
7. Johnson NS, Saal HM, Lovell AM, Schorry EK: Social and emotional problems in children with neurofibromatosis type 1: evidence and proposed interventions. *J Pediatr.* 1999, 134:767-72. [10.1016/s0022-3476\(99\)70296-9](#)
8. Noll RB, Reiter-Purtill J, Moore BD, Schorry EK, Lovell AM, Vannatta K, Gerhardt CA: Social, emotional, and behavioral functioning of children with NF1. *Am J Med Genet A.* 2007, 143A:2261-73. [10.1002/ajmg.a.31923](#)
9. Torres Nupan MM, Velez Van Meerbeke A, López Cabra CA, Herrera Gomez PM: Cognitive and behavioral disorders in children with neurofibromatosis type 1. *Front Pediatr.* 2017, 5:227. [10.3389/fped.2017.00227](#)
10. McNeill AM, Hudock RL, Foy AM, et al.: Emotional functioning among children with neurofibromatosis type 1 or Noonan syndrome. *Am J Med Genet A.* 2019, 179:2433-46. [10.1002/ajmg.a.61361](#)
11. Kenborg L, Andersen EW, Duun-Henriksen AK, et al.: Psychiatric disorders in individuals with neurofibromatosis 1 in Denmark: a nationwide register-based cohort study. *Am J Med Genet A.* 2021, 185:3706-16. [10.1002/ajmg.a.62436](#)
12. Hyman SL, Shores A, North KN: The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. *Neurology.* 2005, 65:1037-44. [10.1212/01.wnl.0000179303.72345.ce](#)
13. Eijk S, Mous SE, Dieleman GC, et al.: Autism spectrum disorder in an unselected cohort of children with neurofibromatosis type 1 (NF1). *J Autism Dev Disord.* 2018, 48:2278-85. [10.1007/s10803-018-3478-0](#)
14. Morris SM, Gutmann DH: A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1. *Neurology.* 2018, 90:377-9. [10.1212/WNL.0000000000005000](#)
15. Morotti H, Mastel S, Keller K, Barnard RA, Hall T, O'Roak BJ, Fombonne E: Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1. *Dev Med Child Neurol.* 2021, 63:226-32. [10.1111/dmcn.14558](#)
16. Sanchez-Marco SB, Lopez-Pison J, Serrano-Vinuales I, Troyas-Fernandez de Garayalde L, Lafuente-Hidalgo M, Monge-Galindo L: Neurofibromatosis type 1 and attention-deficit disorder. Our current experience (Article in Spanish). *Rev Neurol.* 2019, 68:7-10.
17. Mautner VF, Kluwe L, Thakker SD, Leark RA: Treatment of ADHD in neurofibromatosis type 1. *Dev Med Child Neurol.* 2002, 44:164-70. [10.1017/s0012162201001876](#)
18. Hirabaru K, Matsuo M: Neurological comorbidity in children with neurofibromatosis type 1. *Pediatr Int.* 2018, 60:70-5. [10.1111/ped.13388](#)
19. Payne JM, Haebich KM, MacKenzie R, et al.: Cognition, ADHD symptoms, and functional impairment in children and adolescents with neurofibromatosis type 1. *J Atten Disord.* 2021, 25:1177-86. [10.1177/1087054719894384](#)
20. Cohen JS, Levy HP, Sloan J, Dariotis J, Biesecker BB: Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life. *Clin Genet.* 2015, 88:425-30. [10.1111/cge.12551](#)
21. Doorley JD, Greenberg J, Bakhshaie J, Fishbein NS, Vranceanu AM: Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis. *J Neurooncol.* 2021, 154:257-63. [10.1007/s11060-021-03826-3](#)
22. Doser K, Andersen EW, Kenborg L, et al.: Clinical characteristics and quality of life, depression, and anxiety in adults with neurofibromatosis type 1: a nationwide study. *Am J Med Genet A.* 2020, 182:1704-15. [10.1002/ajmg.a.61627](#)
23. Schwetye KE, Gutmann DH: Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions. *Expert Rev Neurother.* 2014, 14:1139-52. [10.1586/14737175.2014.953931](#)
24. Ferner RE, Huson SM, Evans DG: Neurofibromatoses in Clinical Practice. Springer Science+Business Media, Heidelberg, Germany; 2011.
25. Bottesi G, Spoto A, Trevisson E, Zuccarello D, Vidotto G, Cassina M, Clementi M: Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement. *Br J Dermatol.* 2020, 182:1449-57. [10.1111/bjd.18363](#)
26. Kaczorowski JA, Smith TF, Shrewsbury AM, Thomas LR, Knopik VS, Acosta MT: Neurofibromatosis type 1 implicates ras pathways in the genetic architecture of neurodevelopmental disorders. *Behav Genet.* 2020, 50:191-202. [10.1007/s10519-020-09991-x](#)
27. Prochnow A, Bluschke A, Novotna B, von der Hagen M, Beste C: Feedback-based learning of timing in attention-deficit/hyperactivity disorder and neurofibromatosis type 1. *J Int Neuropsychol Soc.* 2021, 5:1-10. [10.1017/S1355617721000072](#)
28. Pobric G, Taylor JR, Ramalingam HM, et al.: Cognitive and electrophysiological correlates of working memory impairments in neurofibromatosis type 1 (Epub ahead of print). *J Autism Dev Disord.* 2021, [10.1007/s10803-021-05043-3](#)
29. Maloney SE, Chandler KC, Anastasaki C, Rieger MA, Gutmann DH, Dougherty JD: Characterization of early communicative behavior in mouse models of neurofibromatosis type 1. *Autism Res.* 2018, 11:44-58. [10.1002/aur.1853](#)
30. Deraredj Nadim W, Chaumont-Dubel S, Madouri F, et al.: Physical interaction between neurofibromin and serotonin 5-HT₆ receptor promotes receptor constitutive activity. *Proc Natl Acad Sci U S A.* 2016, 113:12310-5. [10.1073/pnas.1600914113](#)
31. Brown JA, Xu J, Diggs-Andrews KA, Wozniak DF, Mach RH, Gutmann DH: PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. *Exp Neurol.* 2011, 232:333-8.

- 10.1016/j.expneurol.2011.09.005
32. Li Y, Li Y, McKay RM, Riethmacher D, Parada LF: Neurofibromin modulates adult hippocampal neurogenesis and behavioral effects of antidepressants. *J Neurosci*. 2012, 32:3529-39. [10.1523/JNEUROSCI.3469-11.2012](#)
33. Shen S, Battersby S, Weaver M, Clark E, Stephens K, Harmar AJ: Refined mapping of the human serotonin transporter (SLC6A4) gene within 17q11 adjacent to the CPD and NF1 genes. *Eur J Hum Genet*. 2000, 8:75-8. [10.1038/sj.ejhg.5200400](#)
34. Bellivier F, Laplanche JL, Fournier G, Wolkenstein P: Serotonin transporter gene polymorphism and psychiatric disorders in NF1 patients. *Am J Med Genet*. 2001, 105:758-60. [10.1002/ajmg.10037](#)
35. Brown JA, Emnett RJ, White CR, et al.: Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. *Hum Mol Genet*. 2010, 19:4515-28. [10.1093/hmg/ddq382](#)
36. Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Wozniak DF, Gutmann DH: Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. *Ann Neurol*. 2013, 73:309-15. [10.1002/ana.23793](#)
37. Cui Y, Costa RM, Murphy GG, et al.: Neurofibromin regulation of ERK signaling modulates GABA release and learning. *Cell*. 2008, 135:549-60. [10.1016/j.cell.2008.09.060](#)
38. Wozniak DF, Diggs-Andrews KA, Conyers S, et al.: Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice. *PLoS One*. 2013, 8:e66024. [10.1371/journal.pone.0066024](#)
39. van der Voet M, Harich B, Franke B, Schenck A: ADHD-associated dopamine transporter, latrophilin and neurofibromin share a dopamine-related locomotor signature in *Drosophila*. *Mol Psychiatry*. 2016, 21:565-73. [10.1038/mp.2015.55](#)
40. Mustafin RN, Enikeeva RF, Malykh SB, Valinurov RG, Khusnutdinova EK: Genetics and epigenetics of attention deficit hyperactivity disorder (Article in Russian). *Zh Nevrol Psikhiatr Im S S Korsakova*. 2018, 118:106-10. [10.17116/jnevro2018118091106](#)
41. Donarum EA, Halperin RF, Stephan DA, Narayanan V: Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex. *BMC Neurosci*. 2006, 7:22. [10.1186/1471-2202-7-22](#)
42. Sutton LP, Muntean BS, Ostrovskaya O, et al.: NF1-cAMP signaling dissociates cell type-specific contributions of striatal medium spiny neurons to reward valuation and motor control. *PLoS Biol*. 2019, 17:e3000477. [10.1371/journal.pbio.3000477](#)
43. Anastasaki C, Woo AS, Messiaen LM, Gutmann DH: Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. *Hum Mol Genet*. 2015, 24:3518-28. [10.1093/hmg/ddv103](#)
44. Robinson JE, Coughlin GM, Hori AM, et al.: Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. *Elife*. 2019, 8:2-4. [10.7554/eLife.48983](#)
45. Lion-François L, Gueyffier F, Mercier C, et al.: The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial. *Orphanet J Rare Dis*. 2014, 9:142. [10.1186/s13023-014-0142-4](#)
46. Pride NA, Barton B, Hutchins P, et al.: Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial. *BMJ Open*. 2018, 8:e021800. [10.1136/bmjopen-2018-021800](#)
47. Templer AK, Titus JB, Gutmann DH: A neuropsychological perspective on attention problems in neurofibromatosis type 1. *J Atten Disord*. 2013, 17:489-96. [10.1177/1087054711433422](#)
48. Lukkes JL, Drozd HP, Fitz SD, Molosh AI, Clapp DW, Shekhar A: Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model. *J Neurodev Disord*. 2020, 12:2. [10.1186/s11689-019-9304-y](#)
49. Stryjer R, Strous RD, Shaked G, et al.: Amantadine as augmentation therapy in the management of treatment-resistant depression. *Int Clin Psychopharmacol*. 2003, 18:93-6. [10.1097/00004850-200303000-00005](#)